Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

7- or 30-day recall questions accurately capture self-reported LUTS

28 Oct 2019

Seven- and 30-day recalled reports correspond well with averaged daily reports by men and women with lower urinary tract symptoms (LUTS), a recent study has shown.

“Systematic bias was minimal, suggesting that 7- and 30-day recall periods for self-reported LUTS are reasonable,” the investigators said.

This study recruited a total of 261 female and 254 male participants from six US tertiary care sites. Eighteen items representing seven symptoms, which include voiding and postmicturition symptoms, were evaluated.

Item responses on the daily forms were then averaged for a 7- or a 30-day period and compared to the corresponding 7-or 30-day recall version of the item. Analyses were item- and gender-specific.

Pearson correlation was used to evaluate within-person concordance. Bias (systematic over-reporting or under-reporting) was calculated as the difference between the recalled item and the averaged daily item score and was reported as a percent of the item scale.

All correlations were above 0.60, with those between averaged daily reports and recalled reports ranging from 0.72 to 0.89 for 7 days and from 0.71 to 0.09 for 30 days among women, and from 0.68 to 0.90 and 0.68 to 0.95, respectively, among men.

Moreover, systematic bias was not observed in most items, and the median percent bias did not exceed 10 percent for any item. However, a subset of individuals was found to have bias exceeding ±10 percent for some items.

“Self-reported measurement tools often provide a recall period (eg, “In the past 7 days…”),” the investigators noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.